DiscGenics

DiscGenics, founded in 2007, is a pioneering biopharmaceutical company in the United States with the slogan "REVOLUTIONIZING CARE FOR CHRONIC BACK PAIN." Specializing in biotechnology and healthcare, the company is dedicated to developing regenerative cell-based therapies aimed at alleviating pain and restoring function in patients with degenerative spinal diseases. DiscGenics' primary focus lies in harnessing the restorative potential of cells native to the intervertebral disc, offering hope for millions of individuals suffering from the debilitating effects of back pain. The company's flagship product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy designed for patients with mild to moderate degenerative disc disease. Notably, DiscGenics received a substantial $50.00M Series C investment on 25 August 2020, with notable investors including Mitsubishi UFJ Capital, Medical Incubator Japan, Ci:z Investment, Najeeb Thomas, and CareNet. With its innovative approach and recent investment infusion, DiscGenics seems poised to make a significant impact in revolutionizing the treatment of chronic back pain.